Close

Press Releases

Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl

Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD),...

Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships

Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers...

Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment

Novartis presented today a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare...

Pfizer Inc, Study Shows Adding INSPRA to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure

Pfizer Inc. announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization...

Forest Laboratories Enters Collaboration on Bystolic(R) and Savella(R)

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic(R)...

Endo Pharmaceuticals Announces That FDA Eliminates Need for Advisory Committee Meeting to Discuss New Formulation of Long-Acting Oxymorphone

  Endo Pharmaceuticals announced that the U.S. FDA has informed the company that FDA no longer sees a need to convene a joint meeting...

Abbott Wins Two Scrip Awards Recognizing Excellence in Pharmaceutical and Biotech Industries

Abbott Park, Illinois Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read